Results from a large independent study on peri-implantitis have shown there are substantial differences between implant systems and the occurrence of peri-implantitis, an inflammation around dental implants that leads to implant loss if not treated.

Large retrospective study1 of dental implants in broad clinical setting: 427 patients, 1578 implants from various manufacturers, 9-year follow-up

Significantly lower odds ratios for moderate/severe peri-implantitis with Straumann Tissue Level SLA implants than with the other implant systems evaluated

Study published in peer-reviewed Journal of Dental Research

Findings highly relevant for dentists who base their choice of implant on independent clinical evidence

Using the national data register of the Swedish Social Insurance Agency, Dr Jan Derks and colleagues from Gothenburg University in Sweden randomly selected 427 implant patients from a population of approximately 25 000 patients treated 9 years previously by more than 800 clinicians. The selected patients were assessed for typical indicators of peri-implantitis, including bone loss, bleeding, and pocket depth around their implants.

peri-implantitis odds ratio after 9-y examination

With some exceptions, Nobel Biocare implants had a TiUnite® surface and Astra Tech implants had a TiOblast® surface; all Straumann implants were Tissue Level SLA®.

The investigators observed that the extent of moderate/severe peri-implantitis2  differed between the implant systems and that the odds ratio of developing it was more than three times higher in the patients treated with Nobel Biocare and Astra Tech Implant System implants. With some exceptions, the Nobel Biocare implants had a TiUnite® surface and the Astra Tech implants had a TiOblast® surface; all the Straumann implants were Tissue Level SLA®.

The results, which were presented at the 2015 EAO and have now been published in the Journal of Dental Research 1 , add weight to previously reported findings showing high success rates with Straumann implants3,4,5,6,7. The findings are highly relevant for dentists who base their choice of implant on independent clinical evidence.

1 J. Derks, D. Schaller, J. Håkansson, J.L. Wennström, C. Tomasi, and T. Berglundh: Effectiveness of Implant Therapy Analyzed in a Swedish Population: Prevalence of Peri-implantitis: Journal of Dental Research 2016, Vol. 95(1) 43–49. 2 Defined as bleeding on probing/ suppuration and bone loss > 2mm. 3 Buser D et al Clin Implant Dent Relat Res. 2012 Dec;14(6):839-51. 4 Roccuzzo M et al Clin Oral Implants Res. 2014 Oct;25(10):1105-12. 5 van Velzen FJ et al Clin Oral Implants Res. 2014 Nov 5. 6 Fischer K et al Clin Implant Dent Relat Res. 2012 Dec;14(6):808-15. 7 Derks J. et al. Published online before print December 11, 2014, doi: 10.1177/0022034514563077 JDR December 11, 2014.